Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to Pfizer stock (NYSE: PFE), given its better growth prospects and comparatively lower valuation of 3.0x trailing revenues, compared to 4.7x for Pfizer.

Is Bristol Myers Squibb Stock A Better Pick Over This Vaccine Company?

During the JPM Healthcare conference last week, Bristol Myers gave a bullish presentation outlining how it plans to grow revenues in the low double digits this decade.

Bristol Myers Squibb Looks Strong In 2022, Century Deal Can Help Establish Cell Therapy Leadership

Gilead Sciences

Seagen

Vertex Pharmaceuticals

These potential corporate combinations would make a lot of sense.

4 Biotech Acquisitions We'd Like to See in 2022

In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.82, marking a -1.01% move from the previous day.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol Myers Squibb Co (NYSE: BMY).

Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum

BMY appears ready to break out to new highs. BMY offers a significant dividend that is well covered.

Bristol Myers Squibb Shares Are Still Undervalued

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Bristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving Average

BioAtla, Inc

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).  Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio.

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

Shares of Bristol-Myers Squibb Co (NYSE: BMY) are up more than 3.0% on Monday after the pharmaceutical company said it will repurchase $5.0 billion worth of its stock in Q1. CEO says business development is a priority Interestingly, however, CEO Giovanni Caforio says business development is a priority for Bristol-Myers.

Expert opinion: ‘Bristol-Myers is a buy'

Abbott Labs

Comcast

Sellers continue to push their advantage making it necessary to play defense to win. Here are three top stock trades for the new week.

3 Top Stock Trades for the Week of Jan. 10, 2022

Bristol Myers Squibb Co (NYSE: BMY) kicked off the Big Pharma presentations at the J.P. Morgan healthcare conference.

Bristol Myers Squibb Shares Jump After J.P. Morgan Healthcare Conference Presentation

Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced a $5 billion buyback and issued FY22 financial guidance. Bristol-Myers said it plans to execute the accelerated share repurchase agreement during the first quarter of 2022.

Why Bristol-Myers Squibb Shares Are Trading Higher Today

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Bristol Myers Squibb (BMY) Crossed Above the 20-Day Moving Average: What That Means for Investors

Century Therapeutics

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors.  The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform.

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

Last month we discussed that there are good chances of a rise in Bristol Myers Squibb stock based on its historical performance. BMY stock is up 8% over the last month, primarily driven by increased investor interest after the company announced a 10% increase in its quarterly dividend, and that it.

What's Happening With Bristol Myers Squibb Stock?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio to discover and advance next-generation T cell therapies for the treatment of solid tumors. “The decision by Bristol Myers Squibb to expand our collaboration and

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

PHILADELPHIA & NEW YORK--(BUSINESS WIRE)---- $BMY--Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference

Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference

AstraZeneca

Eli Lilly

Merck

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

3 Big FDA Approvals to Watch For in Q1 2022

Intuitive Surgical

These two healthcare giants have a lot going their way.

2 Top Healthcare Stocks That Could Make You Richer in 2022 and Beyond

Amgen

Novocure

United Therapeutics

SPDR S&P Pharmaceuticals ETF

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 Pharmaceutical Stocks That Could Make You Rich

AbbVie

Biogen

Hoth Therapeutics

Johnson & Johnson

Longeveron

Pfizer

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

These Emerging Biotechs Could Beat Alzheimer's Disease

Caterpillar

General Dynamics

Hormel Foods

Lowe's

Mastercard

Oracle

Toronto-Dominion Bank

Verizon

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: January 6-17, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--ZS selected by biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE: BMY) to support its worldwide commercial analytics organization.

Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference

News for Bristol-Myers Stock (BMY)